VEGFA and hepatocellular carcinoma: In 2020, atezolizumab (ATZ), an anti-programmed death ligand 1 (PD-L1) monoclonal antibody, and bevacizumab (BEV), an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, were approved as first-line therapy for unresectable or metastatic HCC, which changed the treatment landscape for advanced HCC [5].